DNLI

As of 2026-10-26, DNLI scores 20out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. DNLI trades at $18.66, within its fair-value band.

DNLI scores 20 out of 100 on QNTM's five-factor model — a low-conviction reading — at 20 the factor profile is among the weaker names in the universe. Its strongest factor is sentiment at 36 (soft), where analyst and positioning signals are improving, followed by volume at 34. The weakest is value at 0, where valuation looks stretched. Among Healthcare stocks it sits in the lower 2% of Healthcare names by composite.

On valuation, DNLI is priced near the floor of its own recent range — the cheap end on the model's valuation read. The blended composite before the macro overlay was 20. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on DNLI, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where DNLI sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for DNLI runs $16.62–$27.06. Current price $18.66 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.